Jake Simson is a Partner at RA Capital Management who works on both public and private investments. He currently serves as a Board Director for Xenikos, B.V, Tyra Biosciences, and AavantiBi. Previously, Jake covered solid tumor oncology landscapes. Jake holds a BS in Materials Science and Engineering from MIT and a PhD in Biomedical Engineering from Johns Hopkins University. In his doctoral research, he investigated clinically translatable treatments for musculoskeletal tissue repair using injectable hydrogels.